Cambridge Sees Pfizer Pursuit as Disrupting Science Hub

Researchers in the English city of Cambridge, birthplace of the world’s best-selling drug and 47 Nobel Prizes in medicine and chemistry through its university, have little faith in Pfizer Inc.’s vision for AstraZeneca Plc.

AstraZeneca has been planning to move its headquarters from London to Cambridge in 2016 at a cost of 330 million pounds ($558 million). Now, with New York-based Pfizer Inc. bidding to buy AstraZeneca, the fate of British science is up in the air.